DNB Asset Management AS lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 15.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,483 shares of the life sciences company’s stock after purchasing an additional 2,423 shares during the quarter. DNB Asset Management AS’s holdings in Illumina were worth $6,132,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in ILMN. Nuveen Asset Management LLC grew its stake in Illumina by 67,829.8% in the second quarter. Nuveen Asset Management LLC now owns 2,260,705 shares of the life sciences company’s stock valued at $832,279,000 after purchasing an additional 2,257,377 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Illumina by 64.8% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,315,437 shares of the life sciences company’s stock worth $400,182,000 after purchasing an additional 517,226 shares in the last quarter. Nikko Asset Management Americas Inc. boosted its holdings in shares of Illumina by 80.9% in the 3rd quarter. Nikko Asset Management Americas Inc. now owns 753,124 shares of the life sciences company’s stock valued at $229,115,000 after buying an additional 336,821 shares during the last quarter. Viking Global Investors LP boosted its holdings in shares of Illumina by 16.0% in the 2nd quarter. Viking Global Investors LP now owns 1,371,087 shares of the life sciences company’s stock valued at $504,766,000 after buying an additional 188,763 shares during the last quarter. Finally, Natixis grew its stake in shares of Illumina by 481.7% in the second quarter. Natixis now owns 109,334 shares of the life sciences company’s stock valued at $40,251,000 after buying an additional 90,540 shares in the last quarter. 91.75% of the stock is currently owned by institutional investors and hedge funds.
In other Illumina news, SVP Charles Dadswell sold 193 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $297.28, for a total transaction of $57,375.04. Following the transaction, the senior vice president now owns 5,069 shares in the company, valued at approximately $1,506,912.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Oene Mark Van sold 625 shares of Illumina stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $330.99, for a total value of $206,868.75. Following the sale, the senior vice president now directly owns 11,578 shares of the company’s stock, valued at approximately $3,832,202.22. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,920 shares of company stock worth $1,262,212. 0.38% of the stock is owned by company insiders.
A number of equities analysts recently weighed in on ILMN shares. Wolfe Research set a $380.00 target price on shares of Illumina and gave the stock a “buy” rating in a report on Friday, October 25th. Cowen reiterated an “outperform” rating and issued a $335.00 price target (up previously from $320.00) on shares of Illumina in a research note on Wednesday, December 18th. Piper Sandler increased their price target on shares of Illumina from $341.00 to $370.00 and gave the company an “overweight” rating in a research note on Thursday, January 9th. ValuEngine lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Friday, December 20th. Finally, Citigroup started coverage on shares of Illumina in a research note on Monday, January 6th. They issued a “buy” rating and a $385.00 target price for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $340.69.
ILMN stock opened at $317.11 on Wednesday. Illumina, Inc. has a one year low of $263.30 and a one year high of $380.76. The stock has a market cap of $49.32 billion, a price-to-earnings ratio of 55.44, a price-to-earnings-growth ratio of 2.26 and a beta of 1.05. The company has a fifty day moving average price of $326.73 and a two-hundred day moving average price of $310.03. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.82 and a quick ratio of 6.15.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 24th. The life sciences company reported $1.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.40 by $0.53. The company had revenue of $907.00 million for the quarter, compared to analyst estimates of $872.65 million. Illumina had a net margin of 28.14% and a return on equity of 22.05%. The company’s revenue was up 6.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.52 earnings per share. Research analysts anticipate that Illumina, Inc. will post 6.45 EPS for the current fiscal year.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.